Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.…
Immunocore to present at upcoming investor conferences
Immunocore Holdings (NASDAQ: IMCR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 524 employees.
The shares were at 26.41 USD on 20 November 2026, down 25.2% over 52 weeks. Its 52-week range is 25.61 USD to 40.72 USD: the price is 35.1% below the high and 3.1% above the low.
Its market capitalisation is 1.36B USD.
Immunocore Holdings reports return on equity of -9.3%, an operating margin of -2.2% and revenue down 1.4% year over year.
It holds more cash than debt, a net cash position of 465.56M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 59.30 USD is 124.5% above the current price. The next earnings report is expected on 24 February 2027.